Saturday 17 October 2026
Export NIKI’s income statement to Excel — free account
Niki BioSolutions, Inc.
NIKI Healthcare Biotechnology
Niki BioSolutions, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $431,400.00, down 66.7% from fiscal 2022.
2.03
0.19
−8.56%
Follow NIKI
| Older periods | Dec '24 | Jun '25 | Sep '25 | Dec '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.22 | 2.99 | 0.56 | 0.78 | |
Current Ratio |
0.22 | 2.99 | 0.56 | 0.78 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
20.08% | 18.39% | 19.20% | 18.29% | |
Debt/Equity |
0.28 | 0.24 | 0.26 | 0.25 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.23 | — | — | 0.00 | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | — | — | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(1.19) | (0.82) | (0.48) | (0.54) | |
Working Capital |
(3.38) | 2.00 | (1.94) | (1.00) | |
Capital Expenditures |
0.06 | — | — | 0.00 | |
Net Current Asset Value |
(3.39) | (1.33) | (1.94) | (1.35) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | — | — | 0.00 | |
| Other line items | |||||
Average Receivables |
1.00 | 0.79 | 0.34 | 0.45 | |
Average Payables |
3.54 | 0.95 | 1.40 | 1.11 | |
Average Assets |
18.50 | 16.26 | 19.11 | 18.20 | |
Average Common Equity |
9.81 | 13.27 | 14.27 | 13.46 |
Columns are period end dates · fundamentals updated 5 Oct 2026